Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)and Presenting With High Platelet Reactivity, as Assessed With a Point of Care Assay, After 600mg Clopidogrel Loading Dose.

Trial Profile

Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)and Presenting With High Platelet Reactivity, as Assessed With a Point of Care Assay, After 600mg Clopidogrel Loading Dose.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Oct 2012

At a glance

  • Drugs Prasugrel (Primary) ; Clopidogrel
  • Indications Embolism and thrombosis; Myocardial infarction
  • Focus Pharmacodynamics
  • Acronyms PRO-GR-4
  • Most Recent Events

    • 07 Nov 2011 Results presented at the 23rd Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics.
    • 29 Sep 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Aug 2011 Planned End Date changed from 1 Jul 2011 to 1 Sep 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top